---
id: nccn-melanoma-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma"
short_title: "Cutaneous Melanoma"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Melanoma
  - Cutaneous Melanoma
  - Metastatic Melanoma
tags:
  - melanoma
  - skin cancer
  - immunotherapy
  - targeted therapy
  - checkpoint inhibitors
publication_date: 2025-01-05
previous_version_date: 2024-01-10
status: current
supersedes: nccn-melanoma-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, staging, treatment, and surveillance of cutaneous melanoma.

## Key Recommendations

### Diagnosis and Staging
- Complete skin examination
- Excisional biopsy preferred
- Breslow thickness, ulceration, mitotic rate assessment
- SLNB for tumors ≥0.8mm or T1b
- PET-CT or CT for advanced staging

### Stage-Dependent Treatment
**Stage 0 (In Situ):**
- Wide local excision with 0.5-1cm margins

**Stage I-II (Localized):**
- Wide local excision (margins based on thickness)
- Consider adjuvant therapy for high-risk stage IIB-IIC

**Stage III (Lymph Node Involvement):**
- Complete lymph node dissection vs. observation after positive SLNB
- Adjuvant immunotherapy (nivolumab or pembrolizumab) recommended

### Adjuvant Therapy
- Pembrolizumab or nivolumab for resected stage III or high-risk stage II
- BRAF/MEK inhibitors (dabrafenib/trametinib) option for BRAF V600 mutant

### Unresectable/Metastatic (Stage IV)
**First-Line:**
- Anti-PD-1 monotherapy (nivolumab, pembrolizumab)
- Nivolumab + ipilimumab (higher response, more toxicity)
- Nivolumab + relatlimab (LAG-3 combination)
- BRAF/MEK for BRAF mutant (dabrafenib/trametinib, encorafenib/binimetinib)

**Subsequent Lines:**
- Switch class (immunotherapy ↔ targeted)
- Clinical trial enrollment
- Consider intralesional therapy (T-VEC) for accessible lesions

### Surveillance
- Regular skin examinations
- Imaging per stage and risk
- Patient education on self-examination
